The J-point phenomenon in aggressive therapy of hypertension: New insights

Current Atherosclerosis Reports

Volumn 14, Issue 2, 2012, Pages 124-129

  Panjrath, Gurusher S ^a   Chaudhari, Sameer ^b   Messerli, Franz H ^c  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b GOOD SAMARITAN HOSPITAL   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Coronary artery disease; Diastolic blood pressure; Hypertension; Mortality; Myocardial infarction; Stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CALCIUM ANTAGONIST; CARVEDILOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; INDAPAMIDE; NEBIVOLOL; PERINDOPRIL; PLACEBO; PRAVASTATIN; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL PLUS VERAPAMIL; VERAPAMIL;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; GERIATRIC PATIENT; HEART ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORECASTING; HUMANS; HYPERTENSION; HYPOTENSION; MALE; MIDDLE AGED; PROGNOSIS; REFERENCE STANDARDS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84861227780     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-012-0233-4     Document Type: Article

References (32)

1. Frank E. Deutsches Archiv Fur Klin. Vol 103; 1911.
2. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectivelydesigned overviews of randomised trials. Lancet. 2003;362 (9395):1527-35. (Pubitemid 37410190)
3. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335(8693):827-38. (Pubitemid 20113741)
4. Lewington S. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360 (9349):1903-13. (Pubitemid 35472129)
5. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA: The Journal of the American Medical Association. 2003;289(19):2560-71.
6. Stewart IMG. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. The Lancet. 1979;313(8121):861-5.
7. Cruickshank J, Thorp J, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;329 (8533):581-4.
8. Waller PC, Isles C, Lever AF, Murray GD, McInnes GT. Does therapeutic reduction of diastolic blood pressure cause death from coronary heart disease? J Hum Hypertens. 1988;2(1):7-10.
9. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The JCurve phenomenon and the treatment of hypertension. JAMA: The Journal of the American Medical Association. 1991;265(4):489-95.
10. Chrysant S. Current status of aggressive blood pressure control. World Journal of Cardiology. 2011;3(3):65-71.
11. Messerli FH, Panjrath GS. The J-Curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol. 2009;54(20):1827-34. This article is a comprehensive review of literature supporting the J-curve relationship and DBP over the past decade and discussion on the underlying pathophysiology.
12. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213-25.
13. Group JS. Principal results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS). Hypertens Res. 2008;31(12):2115-27.
14. Ogihara T, Saruta T, Rakugi H, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly. Hypertension. August 1, 2010 2010;56(2):196-202.
15. Oates DJ, Berlowitz DR, Glickman ME, Silliman RA, Borzecki AM. Blood pressure and survival in the oldest old. J Am Geriatr Soc. 2007;55(3):383-8. (Pubitemid 46331813)
16. Denardo SJ, Gong Y, Nichols WW, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST Substudy. Am J Med. 2010;123(8):719-26.
17. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358 (18):1887-98. (Pubitemid 351620109)
18. de Craen AJM, Gussekloo J, Teng YKO,Macfarlane PW,Westendorp RGJ. Prevalence of five common clinical abnormalities in very elderly people: population based cross sectional study. BMJ. 2003;327 (7407):131-2. (Pubitemid 36876204)
19. Hall W. Representation of blacks, women, and the very elderly (aged080) in 28 major randomized clinical trials. Ethn Dis. 1999;9:333-339.
20. Denardo SJ, Messerli FH, Gaxiola E, et al. Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol. 2010;106(4):498-503.
21. Messerli FH, Bangalore S, Htyte N, Ather S. Authors' Reply. Am J Cardiol. 2009;107(3):491-2.
22. Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP, for the PITTTI. What is the optimal blood pressure in patients after acute coronary syndromes? Circulation 2010;122(21):2142-2151. In this trial of patients with recent acute coronary syndrome, DBP was found to be a predictor of poor prognosis. The J-curve relationship was observed with both SBP and DBP.
23. Fagard RH, Staessen JA, Thijs L, et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med. 2007;167(17):1884-91. (Pubitemid 47481484)
24. Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27(7):1360-9.
25. Bangalore S, Messerli FH, Wun C-C, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) trial. European Heart Journal, 2010. This is a recent study on patients in whom the traditional cardiovascular risk factors were well controlled and demonstrated a Jcurve relationship with DBP.
26. Group AS. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818-828. This is the first large, randomized controlled trial in diabetic patients showing no additional benefit from aggressive blood pressure lowering.
27. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA: The Journal of the American Medical Association 2010;304(1):61-68. This is a substudy of INVEST showing no additional benefit of tight control of SBP in patients with diabetes and/or CAD.
28. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61(3):1086-97. (Pubitemid 34175478)
29. Appel LJ, Wright JT, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363(10):918-29.
30. Agarwal R. Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Clinical Journal of the American Society of Nephrology 2009;4(4):830-837. This trial showed a J-curve relationship between DBP and adverse outcomes in participants with CKD.
31. Mandell BF. Hypertension: do not worry about the "J curve" treat the patient. Cleveland Clinic Journal of Medicine. 2011;78(2):74-4.
32. Bryan W. Hypertension and the "J-Curve". J Am Coll Cardiol. 2009;54(20):1835-6.